Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes

被引:30
作者
Humar, Abhinav [1 ]
Crotteau, Shaina [1 ]
Gruessner, Angelika [1 ]
Kandaswamy, Raja [1 ]
Gruessner, Rainer [1 ]
Payne, William [1 ]
Lake, John [1 ]
机构
[1] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
关键词
immunosuppression; liver transplant; post-transplant diabetes; steroid avoidance;
D O I
10.1111/j.1399-0012.2007.00683.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoinunune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%. p = 0.004). Conclusions: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.
引用
收藏
页码:526 / 531
页数:6
相关论文
共 20 条
[1]   Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression [J].
Berenguer, M ;
Aguilera, V ;
Prieto, M ;
San Juan, F ;
Rayón, JM ;
Benlloch, S ;
Berenguer, J .
JOURNAL OF HEPATOLOGY, 2006, 44 (04) :717-722
[2]  
Citterio F, 2001, TRANSPLANTATION, V72, pSS75
[3]   Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial [J].
Eason, JD ;
Loss, GE ;
Blazek, J ;
Nair, S ;
Mason, AL .
LIVER TRANSPLANTATION, 2001, 7 (08) :693-697
[4]   Early steroid withdrawal after liver transplantation: The Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up [J].
Greig, P ;
Lilly, L ;
Scudamore, C ;
Erb, S ;
Yoshida, E ;
Kneteman, N ;
Bain, V ;
Ghent, C ;
Marotta, P ;
Grant, D ;
Wall, W ;
Tchervenkov, J ;
Barkun, J ;
Roy, A ;
Marleau, D ;
McAlister, V ;
Peltekian, K .
LIVER TRANSPLANTATION, 2003, 9 (06) :587-595
[5]   A safe immunosuppressive protocol in adult-to-adult living related liver transplantation [J].
Gruttadauria, S ;
Cintorino, D ;
Piazza, T ;
Mandala, L ;
Doffria, E ;
Musumeci, A ;
Di Trapani, G ;
Arcadipane, A ;
Scianna, G ;
Spada, M ;
Verzaro, R ;
Volpes, R ;
Vizzini, G ;
Palazzo, U ;
Minervini, M ;
Marsh, JW ;
Marcos, A ;
Gridelli, B .
TRANSPLANTATION PROCEEDINGS, 2006, 38 (04) :1106-1108
[6]   A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - An interim analysis [J].
Kandaswamy, R ;
Melancon, JK ;
Dunn, T ;
Tan, M ;
Casingal, V ;
Humar, A ;
Payne, WD ;
Gruessner, RWG ;
Dunn, DL ;
Najarian, JS ;
Sutherland, DER ;
Gillingham, KJ ;
Matas, AJ .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) :1529-1536
[7]   The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? [J].
Knight, R. J. ;
Kahan, B. D. .
KIDNEY INTERNATIONAL, 2006, 70 (06) :994-999
[8]   Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies [J].
Kumar, MSA ;
Xiao, SG ;
Fyfe, B ;
Sierka, D ;
Heifets, M ;
Moritz, MJ ;
Saeed, MI ;
Kumar, A .
CLINICAL TRANSPLANTATION, 2005, 19 (01) :61-69
[9]   The renal-sparing efficacy of basiliximab in adult living donor liver transplantation [J].
Lin, CC ;
Chuang, FR ;
Lee, CH ;
Wang, CC ;
Chen, YS ;
Liu, YW ;
Jawan, B ;
Chen, CL .
LIVER TRANSPLANTATION, 2005, 11 (10) :1258-1264
[10]   Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage [J].
Liu, CL ;
Fan, ST ;
Lo, CM ;
Chan, SC ;
Ng, IO ;
Lai, CL ;
Wong, J .
LIVER TRANSPLANTATION, 2004, 10 (06) :728-733